Minerva Neurosciences, Inc. SEC filings NERV
Minerva Neurosciences, Inc. has 645 filings in SEC EDGAR's recent list, going back to Feb 14, 2014. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 19, 2026 | — |
| CORRESP | Letter to the SEC | Mar 17, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2026 | — |
| EFFECT | Filing | Jan 6, 2026 | — |
| CORRESP | Letter to the SEC | Jan 2, 2026 | — |
| UPLOAD | Letter from the SEC | Dec 31, 2025 | — |
| EFFECT | Filing | Aug 9, 2023 | — |
| CORRESP | Letter to the SEC | Aug 7, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 7, 2023 | — |
| D | Filing | Jul 3, 2023 | — |
| EFFECT | Filing | Sep 23, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2022 | — |
| CORRESP | Letter to the SEC | Sep 21, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2022 | — |
| CORRESP | Letter to the SEC | Sep 14, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2022 | — |
| SC TO-I/A | Filing | Aug 9, 2021 | — |
| SC TO-I/A | Filing | Aug 2, 2021 | — |
| SC TO-I | Filing | Jul 6, 2021 | — |
| RW | Filing | Apr 11, 2019 | — |
| EFFECT | Filing | Aug 24, 2018 | — |
| CORRESP | Letter to the SEC | Aug 22, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2018 | — |
| D | Filing | Mar 18, 2016 | — |
| EFFECT | Filing | Jul 27, 2015 | — |
| CORRESP | Letter to the SEC | Jul 24, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2015 | — |
| EFFECT | Filing | May 11, 2015 | — |
| D | Filing | Mar 24, 2015 | — |
| CT ORDER | Filing | Jul 7, 2014 | — |
| EFFECT | Filing | Jun 30, 2014 | — |
| CORRESP | Letter to the SEC | Jun 30, 2014 | — |
| CORRESP | Letter to the SEC | Jun 30, 2014 | — |
| CERTNAS | Auto-generated paper document | Jun 24, 2014 | — |
| 8-A12B | Filing | Jun 23, 2014 | — |
| CORRESP | Letter to the SEC | Jun 23, 2014 | — |
| CORRESP | Letter to the SEC | Jun 23, 2014 | — |
| CORRESP | Letter to the SEC | Jun 10, 2014 | — |
| CORRESP | Letter to the SEC | Apr 23, 2014 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2014 | — |
| CORRESP | Letter to the SEC | Apr 9, 2014 | — |
| DRS/A | Filing | Mar 31, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 14, 2014 | — |
| DRSLTR | Filing | Feb 14, 2014 | — |
| DRS | Filing | Feb 14, 2014 | — |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NERV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Burlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1598646
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.